Shopping Cart 0
Cart Subtotal
USD 0

Arbutus Biopharma Corp (ABUS) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Single User License
USD 250

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: No
Copy Option: No
Download Option: No
Deliverable Format : PDF viewable on the website via username

Site License
USD 500

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Download Option: Yes
Deliverable Format : Excel, PDF viewable on the website via username

Corporate User License
USD 750

Details

Summary

Arbutus Biopharma Corp (Arbutus Biopharma), formerly Tekmira Pharmaceuticals Corporation, is a biopharmaceutical company that focuses on the discovery, development and commercialization of proprietary drugs and drug delivery systems indicated for the treatment of chronic hepatitis B infection. Its pipeline includes HBV candidates such as ARB-1467 for HBsAg expression in patients chronically infected with HBV; AB-452 (HBV RNA destabilizer); and capsid assembly inhibitor (AB-423 and AB-506). The company also has cancer, anti-viral and metabolic programs. Arbutus Biopharma develops product candidates based on its lipid nanoparticle (LNP) delivery technology. It has operational presence in the US and Canada. Arbutus Biopharma is headquartered in British Columbia, Canada.

Arbutus Biopharma Corp (ABUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Arbutus Biopharma and Roivant Sciences to Form Joint Venture 11

Spring Bank Pharma Enters into Agreement with Arbutus Biopharma 13

Merger 14

Tekmira Pharma Merges with OnCore Biopharma 14

Licensing Agreements 16

Arbutus Biopharma Enters into License Agreement with Gritstone Oncology 16

Dicerna Pharma Enters into Licensing Agreement with Tekmira Pharma 17

Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 18

Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 19

Arbutus Biopharma Enters into Research and Licensing Agreement with Saint Louis University Liver Center 20

Tekmira Enters Into Option For Licensing Agreement With Monsanto 21

Equity Offering 22

Arbutus Biopharma Raises USD66.4 Million in Second and Final Tranche of Private Placement of Preferred Shares 22

Arbutus Biopharma Raises USD50 Million in First Tranche of Private Placement of Preferred Shares 24

Tekmira Pharma Raises USD151.9 Million in Public Offering of Shares 26

Tekmira Pharma Completes Public Offering Of Shares For USD 60.6 Million 28

Tekmira Pharma Completes Underwriters' Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For USD 34.5 Million 29

Arbutus Biopharma Corp-Key Competitors 30

Arbutus Biopharma Corp-Key Employees 31

Arbutus Biopharma Corp-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Aug 02, 2018: Arbutus reports 2018 second quarter financial results and provides corporate update 33

May 03, 2018: Arbutus Announces Corporate Update and First Quarter 2018 Financial Results 36

Mar 14, 2018: Arbutus Announces Corporate Update and Year-End 2017 Financial Results 38

Nov 02, 2017: Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results 41

Aug 03, 2017: Arbutus Announces Corporate Update and Second Quarter 2017 Financial Results 44

May 04, 2017: Arbutus Announces Corporate Update and First Quarter 2017 Financial Results 47

Mar 21, 2017: Arbutus Announces Year-End 2016 Financial Results 49

Corporate Communications 52

Jun 07, 2018: Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer 52

Feb 13, 2018: Arbutus Announces Resignation Of Bruce Cousins As Chief Financial Officer 53

Mar 23, 2017: Arbutus Announces Appointment of Daniel Burgess to Board of Directors 54

Legal and Regulatory 55

Feb 22, 2018: Arbutus Settles Litigation, Terminating Acuitas' Rights to LNP Technology 55

Apr 13, 2017: Arbutus Injunction Survives Attempted Appeal by Acuitas 56

Feb 08, 2017: Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology 57

Product News 58

10/03/2017: Arbutus to Present Data on HBV Drug Candidate AB-423 at 2017 AASLD Liver Meeting 58

10/03/2017: Arbutus to Present Data on HBV Drug Candidate AB-452 at 2017 AASLD Liver Meeting 59

Clinical Trials 60

Apr 12, 2018: Arbutus Biopharma Presents Preclinical Data of HBV Drug Candidate AB-729 at EASL 2018 60

Oct 03, 2017: Arbutus to Present Data on HBV Drug Candidate ARB-1467 at 2017 AASLD Liver Meeting 61

Sep 25, 2017: Arbutus Announces Topline Results for ARB-1467 Phase II Cohort 4 62

Apr 22, 2017: Arbutus Announces ARB-1467 Data Presentation at EASL 63

Other Significant Developments 64

Oct 09, 2018: Arbutus provides update on HBV development programs and announces appointment of Dr. Gaston Picchio as chief development officer 64

Jul 10, 2018: Arbutus Presents Corporate Update on Key Milestones 66

Feb 08, 2018: Arbutus Consolidates HBV Business Around Warminster, PA Site 67

Appendix 68

Methodology 68

About GlobalData 68

Contact Us 68

Disclaimer 68


List Of Figure

List of Figures

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arbutus Biopharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arbutus Biopharma and Roivant Sciences to Form Joint Venture 11

Spring Bank Pharma Enters into Agreement with Arbutus Biopharma 13

Tekmira Pharma Merges with OnCore Biopharma 14

Arbutus Biopharma Enters into License Agreement with Gritstone Oncology 16

Dicerna Pharma Enters into Licensing Agreement with Tekmira Pharma 17

Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 18

Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 19

Arbutus Biopharma Enters into Research and Licensing Agreement with Saint Louis University Liver Center 20

Tekmira Enters Into Option For Licensing Agreement With Monsanto 21

Arbutus Biopharma Raises USD66.4 Million in Second and Final Tranche of Private Placement of Preferred Shares 22

Arbutus Biopharma Raises USD50 Million in First Tranche of Private Placement of Preferred Shares 24

Tekmira Pharma Raises USD151.9 Million in Public Offering of Shares 26

Tekmira Pharma Completes Public Offering Of Shares For USD 60.6 Million 28

Tekmira Pharma Completes Underwriters' Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For USD 34.5 Million 29

Arbutus Biopharma Corp, Key Competitors 30

Arbutus Biopharma Corp, Key Employees 31

Arbutus Biopharma Corp, Subsidiaries 32

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

Arbutus Biopharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

Arbutus Biopharma Corp (Arbutus Biopharma), formerly Tekmira Pharmaceuticals Corporation, is a biopharmaceutical company that focuses on the discovery, development and commercialization of proprietary drugs and drug delivery systems indicated for the treatment of chronic hepatitis B infection. Its pipeline includes HBV candidates such as ARB-1467 for HBsAg expression in patients chronically infected with HBV; AB-452 (HBV RNA destabilizer); and capsid assembly inhibitor (AB-423 and AB-506). The company also has cancer, anti-viral and metabolic programs. Arbutus Biopharma develops product candidates based on its lipid nanoparticle (LNP) delivery technology. It has operational presence in the US and Canada. Arbutus Biopharma is headquartered in British Columbia, Canada.

Arbutus Biopharma Corp (ABUS)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deal Details 11

Partnerships 11

Arbutus Biopharma and Roivant Sciences to Form Joint Venture 11

Spring Bank Pharma Enters into Agreement with Arbutus Biopharma 13

Merger 14

Tekmira Pharma Merges with OnCore Biopharma 14

Licensing Agreements 16

Arbutus Biopharma Enters into License Agreement with Gritstone Oncology 16

Dicerna Pharma Enters into Licensing Agreement with Tekmira Pharma 17

Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 18

Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 19

Arbutus Biopharma Enters into Research and Licensing Agreement with Saint Louis University Liver Center 20

Tekmira Enters Into Option For Licensing Agreement With Monsanto 21

Equity Offering 22

Arbutus Biopharma Raises USD66.4 Million in Second and Final Tranche of Private Placement of Preferred Shares 22

Arbutus Biopharma Raises USD50 Million in First Tranche of Private Placement of Preferred Shares 24

Tekmira Pharma Raises USD151.9 Million in Public Offering of Shares 26

Tekmira Pharma Completes Public Offering Of Shares For USD 60.6 Million 28

Tekmira Pharma Completes Underwriters' Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For USD 34.5 Million 29

Arbutus Biopharma Corp-Key Competitors 30

Arbutus Biopharma Corp-Key Employees 31

Arbutus Biopharma Corp-Locations And Subsidiaries 32

Head Office 32

Other Locations & Subsidiaries 32

Recent Developments 33

Financial Announcements 33

Aug 02, 2018: Arbutus reports 2018 second quarter financial results and provides corporate update 33

May 03, 2018: Arbutus Announces Corporate Update and First Quarter 2018 Financial Results 36

Mar 14, 2018: Arbutus Announces Corporate Update and Year-End 2017 Financial Results 38

Nov 02, 2017: Arbutus Announces Corporate Update and Third Quarter 2017 Financial Results 41

Aug 03, 2017: Arbutus Announces Corporate Update and Second Quarter 2017 Financial Results 44

May 04, 2017: Arbutus Announces Corporate Update and First Quarter 2017 Financial Results 47

Mar 21, 2017: Arbutus Announces Year-End 2016 Financial Results 49

Corporate Communications 52

Jun 07, 2018: Arbutus Strengthens Management Team With Appointment of David C. Hastings as New Chief Financial Officer 52

Feb 13, 2018: Arbutus Announces Resignation Of Bruce Cousins As Chief Financial Officer 53

Mar 23, 2017: Arbutus Announces Appointment of Daniel Burgess to Board of Directors 54

Legal and Regulatory 55

Feb 22, 2018: Arbutus Settles Litigation, Terminating Acuitas' Rights to LNP Technology 55

Apr 13, 2017: Arbutus Injunction Survives Attempted Appeal by Acuitas 56

Feb 08, 2017: Arbutus Is Granted a Pre-trial Injunction Restraining Acuitas From Entering Into Agreements Sublicensing Arbutus LNP Technology 57

Product News 58

10/03/2017: Arbutus to Present Data on HBV Drug Candidate AB-423 at 2017 AASLD Liver Meeting 58

10/03/2017: Arbutus to Present Data on HBV Drug Candidate AB-452 at 2017 AASLD Liver Meeting 59

Clinical Trials 60

Apr 12, 2018: Arbutus Biopharma Presents Preclinical Data of HBV Drug Candidate AB-729 at EASL 2018 60

Oct 03, 2017: Arbutus to Present Data on HBV Drug Candidate ARB-1467 at 2017 AASLD Liver Meeting 61

Sep 25, 2017: Arbutus Announces Topline Results for ARB-1467 Phase II Cohort 4 62

Apr 22, 2017: Arbutus Announces ARB-1467 Data Presentation at EASL 63

Other Significant Developments 64

Oct 09, 2018: Arbutus provides update on HBV development programs and announces appointment of Dr. Gaston Picchio as chief development officer 64

Jul 10, 2018: Arbutus Presents Corporate Update on Key Milestones 66

Feb 08, 2018: Arbutus Consolidates HBV Business Around Warminster, PA Site 67

Appendix 68

Methodology 68

About GlobalData 68

Contact Us 68

Disclaimer 68


List Of Figure

List of Figures

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 7

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 9


List Of Table

List of Tables

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Key Facts, 2017 2

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 6

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 7

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 8

Arbutus Biopharma Corp, Deals By Therapy Area, 2012 to YTD 2018 9

Arbutus Biopharma Corp, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 10

Arbutus Biopharma and Roivant Sciences to Form Joint Venture 11

Spring Bank Pharma Enters into Agreement with Arbutus Biopharma 13

Tekmira Pharma Merges with OnCore Biopharma 14

Arbutus Biopharma Enters into License Agreement with Gritstone Oncology 16

Dicerna Pharma Enters into Licensing Agreement with Tekmira Pharma 17

Marina Biotech Enters Into Licensing Agreement With Tekmira Pharma For RNAi Technology 18

Tekmira Pharma Enters Into Licensing Agreement With Alnylam Pharma 19

Arbutus Biopharma Enters into Research and Licensing Agreement with Saint Louis University Liver Center 20

Tekmira Enters Into Option For Licensing Agreement With Monsanto 21

Arbutus Biopharma Raises USD66.4 Million in Second and Final Tranche of Private Placement of Preferred Shares 22

Arbutus Biopharma Raises USD50 Million in First Tranche of Private Placement of Preferred Shares 24

Tekmira Pharma Raises USD151.9 Million in Public Offering of Shares 26

Tekmira Pharma Completes Public Offering Of Shares For USD 60.6 Million 28

Tekmira Pharma Completes Underwriters' Exercise Of Full Over-Allotment Option Of Public Offering Of Shares For USD 34.5 Million 29

Arbutus Biopharma Corp, Key Competitors 30

Arbutus Biopharma Corp, Key Employees 31

Arbutus Biopharma Corp, Subsidiaries 32

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

Arbutus Biopharma Corp, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.